ABUS vs TYL · P/E 5.4, rev $6.2M vs P/E 89, rev $2.14B
Arbutus Biopharma Corp (ABUS) versus Tyler Technologies Inc (TYL) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Tyler Technologies Inc (TYL) is a software - application company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported TYL revenue for 2024-12-31 was $2.14B. Net income was $263.0M. Revenue was up 9.5% from 2023-12-31 to 2024-12-31. TYL currently screens at market cap $25.57B and trailing P/E 89.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. TYL currently screens at market cap $25.57B and trailing P/E 89.3.
Not investment advice. Open the ABUS and TYL stock pages for the full models.
Not investment advice.